{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:33:38Z","timestamp":1790314418104,"version":"4.1.0"},"reference-count":115,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Because the number of elderly people is increasing worldwide, and the prevalence of cardiovascular risk factors and cardiovascular diseases increase with age, in current clinical practice we are faced with a large number of geriatric patients requiring oral anticoagulant treatment. Our review highlights some of the particularities of using direct oral anticoagulants (DOACs) in the geriatric population. We focused on the difficulties of managing DOAC treatment in the presence of geriatric syndromes. We highlighted the practical steps needed to overcome the challenges related to the risk of falling, cognitive impairment, swallowing disorders, and polypragmasy to improve patient care. We provided data to help guide the choice of anticoagulant and dose.<\/jats:p>","DOI":"10.3390\/jcm14134396","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T06:10:27Z","timestamp":1750399827000},"page":"4396","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The Use of Direct Oral Anticoagulants (DOACs) in the Geriatric Population\u2014How to Overcome the Challenges of Geriatric Syndromes"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8942-1909","authenticated-orcid":false,"given":"Minerva Codruta","family":"Badescu","sequence":"first","affiliation":[{"name":"Faculty of Medicine, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"III Internal Medicine Clinic, \u201cSt. Spiridon\u201d County Emergency Clinical Hospital, 700111 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Popescu","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"III Internal Medicine Clinic, \u201cSt. Spiridon\u201d County Emergency Clinical Hospital, 700111 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1730-9306","authenticated-orcid":false,"given":"Evelina Maria","family":"Gosav","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"III Internal Medicine Clinic, \u201cSt. Spiridon\u201d County Emergency Clinical Hospital, 700111 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8544-9904","authenticated-orcid":false,"given":"Alexandru Dan","family":"Costache","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"Clinical Rehabilitation Hospital, 700661 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana Elena","family":"Cos\u0103u","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"Clinical Rehabilitation Hospital, 700661 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4792-115X","authenticated-orcid":false,"given":"Adriana","family":"Chetran","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"Cardiology Clinic, \u201cSt. Spiridon\u201d County Emergency Clinical Hospital, 700111 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0218tefania-Teodora","family":"Duca","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"Cardiology Clinic, \u201cSt. Spiridon\u201d County Emergency Clinical Hospital, 700111 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandu","family":"Cucut\u0103","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"Cardiology Clinic, \u201cSt. Spiridon\u201d County Emergency Clinical Hospital, 700111 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ionela L\u0103cr\u0103mioara","family":"\u0218erban","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina Iuliana","family":"Costache Enache","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"Cardiology Clinic, \u201cSt. Spiridon\u201d County Emergency Clinical Hospital, 700111 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1155-7325","authenticated-orcid":false,"given":"Ciprian","family":"Rezus","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"III Internal Medicine Clinic, \u201cSt. Spiridon\u201d County Emergency Clinical Hospital, 700111 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,20]]},"reference":[{"key":"ref_1","unstructured":"United States Census Bureau (2025, April 15). 2023 National Population Projections Tables: Main Series, Available online: https:\/\/www.census.gov\/data\/tables\/2023\/demo\/popproj\/2023-summary-tables.html."},{"key":"ref_2","unstructured":"Eurostat (2025, April 15). Population Structure and Ageing. Available online: https:\/\/ec.europa.eu\/eurostat\/statistics-explained\/index.php?title=Population_structure_and_ageing."},{"key":"ref_3","unstructured":"Economic and Social Commission for Asia and the Pacific (ESCAP) (2025, April 15). Demographic Changes in the Asia and the Pacific. Available online: https:\/\/www.population-trends-asiapacific.org\/population-ageing."},{"key":"ref_4","unstructured":"United Nations. Departament of Economic ans Social Affairs (2025, April 15). World Social Report 2023. Available online: https:\/\/www.un.org\/development\/desa\/dspd\/wp-content\/uploads\/sites\/22\/2023\/01\/2023wsr-chapter1-.pdf."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"k1453","DOI":"10.1136\/bmj.k1453","article-title":"Lifetime risk of atrial fibrillation according to optimal, borderline, or elevated levels of risk factors: Cohort study based on longitudinal data from the Framingham Heart Study","volume":"361","author":"Staerk","year":"2018","journal-title":"BMJ"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e2255838","DOI":"10.1001\/jamanetworkopen.2022.55838","article-title":"Prevalence and Incidence of Atrial Fibrillation Among Older Primary Care Patients","volume":"6","author":"Khurshid","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.amjmed.2004.01.018","article-title":"Deep vein thrombosis and pulmonary embolism in two cohorts: The longitudinal investigation of thromboembolism etiology","volume":"117","author":"Cushman","year":"2004","journal-title":"Am. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s11239-009-0378-3","article-title":"Incidence rates, clinical profile, and outcomes of patients with venous thromboembolism. The Worcester VTE study","volume":"28","author":"Spencer","year":"2009","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"Rienstra","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","article-title":"2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)","volume":"41","author":"Konstantinides","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_11","unstructured":"National Institute for Health and Care Excellence (NICE) (2025, April 15). Falls in Older People: Assessing Risk and Prevention. Available online: https:\/\/www.nice.org.uk\/guidance\/cg161."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1097\/EDE.0b013e3181e89905","article-title":"Risk factors for falls in community-dwelling older people: A systematic review and meta-analysis","volume":"21","author":"Deandrea","year":"2010","journal-title":"Epidemiology"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Mitchell, A., Snowball, J., Welsh, T.J., Watson, M.C., and McGrogan, A. (2021). Prescribing of direct oral anticoagulants and warfarin to older people with atrial fibrillation in UK general practice: A cohort study. BMC Med., 19.","DOI":"10.1186\/s12916-021-02067-5"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1111\/acem.13217","article-title":"Risk of Intracranial Hemorrhage in Ground-level Fall with Antiplatelet or Anticoagulant Agents","volume":"24","author":"Ganetsky","year":"2017","journal-title":"Acad. Emerg. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4297","DOI":"10.1007\/s00068-022-01938-7","article-title":"Treatment and outcomes of anticoagulated geriatric trauma patients with traumatic intracranial hemorrhage after falls","volume":"48","author":"Nederpelt","year":"2022","journal-title":"Eur. J. Trauma Emerg. Surg."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Savioli, G., Ceresa, I.F., Luzzi, S., Gragnaniello, C., Giotta Lucifero, A., Del Maestro, M., Marasco, S., Manzoni, F., Ciceri, L., and Gelfi, E. (2020). Rates of Intracranial Hemorrhage in Mild Head Trauma Patients Presenting to Emergency Department and Their Management: A Comparison of Direct Oral Anticoagulant Drugs with Vitamin K Antagonists. Medicina, 56.","DOI":"10.3390\/medicina56060308"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Kwon, H., Kim, Y.J., Lee, J.H., Kim, S., Kim, Y.J., and Kim, W.Y. (2024). Incidence and outcomes of delayed intracranial hemorrhage: A population-based cohort study. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-70553-w"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s11739-020-02576-w","article-title":"Predictors of post-traumatic complication of mild brain injury in anticoagulated patients: DOACs are safer than VKAs","volume":"16","author":"Cipriano","year":"2021","journal-title":"Intern. Emerg. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.1007\/s00415-024-12424-y","article-title":"Incidence of intracranial bleeding in mild traumatic brain injury patients taking oral anticoagulants: A systematic review and meta-analysis","volume":"271","author":"Karamian","year":"2024","journal-title":"J. Neurol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1007\/s00415-021-10448-2","article-title":"Risk of intracranial hemorrhage with direct oral anticoagulants: A systematic review and meta-analysis of randomized controlled trials","volume":"269","author":"Wu","year":"2022","journal-title":"J. Neurol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"f20","DOI":"10.1093\/ehjcvp\/pvz073","article-title":"Safety and efficacy of non-vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation: Systematic review and meta-analysis of 22 studies and 440 281 patients","volume":"7","author":"Silverio","year":"2021","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Gao, X., Huang, D., Hu, Y., Chen, Y., Zhang, H., Liu, F., and Luo, J. (2022). Direct Oral Anticoagulants vs. Vitamin K Antagonists in Atrial Fibrillation Patients at Risk of Falling: A Meta-Analysis. Front. Cardiovasc. Med., 9.","DOI":"10.3389\/fcvm.2022.833329"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/archinte.159.7.677","article-title":"Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls","volume":"159","author":"Nichol","year":"1999","journal-title":"Arch. Intern. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s40266-021-00870-6","article-title":"Impact of Fall Risk and Direct Oral Anticoagulant Treatment on Quality-Adjusted Life-Years in Older Adults with Atrial Fibrillation: A Markov Decision Analysis","volume":"38","author":"Wei","year":"2021","journal-title":"Drugs Aging"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s41999-023-00811-z","article-title":"Anticoagulant use in older persons at risk for falls: Therapeutic dilemmas-a clinical review","volume":"14","author":"Mitchell","year":"2023","journal-title":"Eur. Geriatr. Med."},{"key":"ref_26","unstructured":"Bristol-Myers Squibb-Pfizer (2025, May 01). Eliquis 5 mg Film-Coated Tablets. Available online: https:\/\/www.medicines.org.uk\/emc\/product\/2878\/smpc."},{"key":"ref_27","unstructured":"Daiichi Sankyo UK Limited (2025, May 01). Lixiana 60 mg Film-Coated Tablets. Available online: https:\/\/www.medicines.org.uk\/emc\/product\/6905\/smpc."},{"key":"ref_28","unstructured":"Bayer PLC (2025, May 01). Xarelto 20 mg Film-Coated Tablets. Available online: https:\/\/www.medicines.org.uk\/emc\/product\/2793\/smpc."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1182\/blood.V126.23.2334.2334","article-title":"Rrivaroxaban-mediated vascular relaxation as a potential cause of headaches and dizziness","volume":"126","author":"Mabley","year":"2015","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.yjmcc.2018.09.003","article-title":"Factor Xa inhibition by rivaroxaban regulates fibrogenesis in human atrial fibroblasts with modulation of nitric oxide synthesis and calcium homeostasis","volume":"123","author":"Chung","year":"2018","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Villari, A., Giurdanella, G., Bucolo, C., Drago, F., and Salomone, S. (2017). Apixaban Enhances Vasodilatation Mediated by Protease-Activated Receptor 2 in Isolated Rat Arteries. Front. Pharmacol., 8.","DOI":"10.3389\/fphar.2017.00480"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.thromres.2019.02.014","article-title":"Direct oral anticoagulant (DOAC)-mediated vasodilation: Role of nitric oxide","volume":"176","author":"Mabley","year":"2019","journal-title":"Thromb. Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1080\/17425255.2023.2287472","article-title":"Pharmacokinetics and pharmacodynamics of direct oral anticoagulants","volume":"19","author":"Hindley","year":"2023","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40560-016-0144-5","article-title":"Profiles of direct oral anticoagulants and clinical usage-dosage and dose regimen differences","volume":"4","author":"Ieko","year":"2016","journal-title":"J. Intensive Care"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"key":"ref_36","unstructured":"(2025, April 20). SAVAYSA [Package Insert], Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/206316s017lbl.pdf."},{"key":"ref_37","unstructured":"(2025, April 20). Lixiana [Product Information]. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lixiana-epar-product-information_en.pdf."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1111\/bcp.15316","article-title":"How to handle a delayed or missed dose of edoxaban in patients with non-valvular atrial fibrillation? A model-informed remedial strategy","volume":"89","author":"Yin","year":"2023","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_40","unstructured":"(2025, April 20). Xarelto [Package Insert], Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/215859s000lbl.pdf."},{"key":"ref_41","unstructured":"(2025, April 20). Xarelto [Package Insert]. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xarelto-epar-product-information_en.pdf."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1080\/17512433.2021.1937126","article-title":"How to handle the delayed or missed dose of rivaroxaban in patients with non-valvular atrial fibrillation: Model-informed remedial dosing","volume":"14","author":"Liu","year":"2021","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_43","unstructured":"(2025, April 20). Pradaxa [Package Insert]. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/pradaxa-epar-product-information_en.pdf."},{"key":"ref_44","unstructured":"(2025, April 20). Pradaxa [Package Insert], Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/022512s047lbl.pdf."},{"key":"ref_45","first-page":"153","article-title":"Evaluation of the single-dose pharmacokinetics and pharmacodynamics of apixaban in healthy Japanese and Caucasian subjects","volume":"10","author":"Frost","year":"2018","journal-title":"Clin. Pharmacol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"801.e5","DOI":"10.1016\/j.ajem.2016.11.035","article-title":"The X factor: Lack of bleeding after an acute apixaban overdose","volume":"35","author":"Leikin","year":"2017","journal-title":"Am. J. Emerg. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1080\/15563650.2016.1204453","article-title":"Anti-Xa activity in apixaban overdose: A case report","volume":"54","author":"Barton","year":"2016","journal-title":"Clin. Toxicol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1160\/TH17-07-0474","article-title":"Apixaban Auto-intoxication: Toxicokinetics and Coagulation Tests","volume":"117","author":"Mast","year":"2017","journal-title":"Thromb. Haemost."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/bcp.13790","article-title":"Self-poisoning with 60 tablets of Apixaban, a pharmacokinetics case report","volume":"85","author":"Franck","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/MBC.0000000000000706","article-title":"Coagulation assays in a case of apixaban overdose","volume":"29","author":"Guadarrama","year":"2018","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000533520","article-title":"Massive Intoxication with 70 Tablets of Apixaban: A Case Report","volume":"6","author":"Kobayashi","year":"2023","journal-title":"Case Rep. Acute Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1177\/0091270009351883","article-title":"Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers","volume":"50","author":"Ogata","year":"2010","journal-title":"J. Clin. Pharmacol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s40780-020-00176-6","article-title":"Pharmacokinetics of anticoagulant edoxaban in overdose in a Japanese patient transported to hospital","volume":"6","author":"Adachi","year":"2020","journal-title":"J. Pharm. Health Care Sci."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.clpt.2005.06.011","article-title":"Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor","volume":"78","author":"Kubitza","year":"2005","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1185\/03007990802361499","article-title":"Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects","volume":"24","author":"Kubitza","year":"2008","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e05023","DOI":"10.1002\/ccr3.5023","article-title":"Conservative management of massive rivaroxaban overdose: A case report and literature review","volume":"9","author":"Ghodsi","year":"2021","journal-title":"Clin. Case Rep."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1160\/TH14-02-0138","article-title":"Massive human rivaroxaban overdose","volume":"112","author":"Lehmann","year":"2014","journal-title":"Thromb. Haemost."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1080\/15563650.2016.1187736","article-title":"Lack of significant bleeding despite large acute rivaroxaban overdose confirmed with whole blood concentrations","volume":"54","author":"Repplinger","year":"2016","journal-title":"Clin. Toxicol."},{"key":"ref_59","first-page":"e34019","article-title":"Management of Massive Rivaroxaban Overdose with Acetaminophen and Isosorbide Mononitrate Overdose","volume":"15","author":"Casey","year":"2023","journal-title":"Cureus"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1365-2125.2007.02899.x","article-title":"The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects","volume":"64","author":"Stangier","year":"2007","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3109\/15563650.2015.1126287","article-title":"Dabigatran deliberate overdose: Two cases and suggestions for laboratory monitoring","volume":"54","author":"Vlad","year":"2016","journal-title":"Clin. Toxicol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1080\/15563650.2016.1187737","article-title":"Idarucizumab for dabigatran overdose","volume":"54","author":"Peetermans","year":"2016","journal-title":"Clin. Toxicol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.ajem.2014.04.031","article-title":"An observational case series of dabigatran and rivaroxaban exposures reported to a poison control system","volume":"32","author":"Stevenson","year":"2014","journal-title":"Am. J. Emerg. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1177\/1060028013513883","article-title":"Evaluation of dabigatran exposures reported to poison control centers","volume":"48","author":"Conway","year":"2014","journal-title":"Ann. Pharmacother."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.annemergmed.2015.07.014","article-title":"An Observational Study of the Factor Xa Inhibitors Rivaroxaban and Apixaban as Reported to Eight Poison Centers","volume":"67","author":"Spiller","year":"2016","journal-title":"Ann. Emerg. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.annemergmed.2017.08.046","article-title":"Assessing Bleeding Risk in Patients with Intentional Overdoses of Novel Antiplatelet and Anticoagulant Medications","volume":"71","author":"Levine","year":"2018","journal-title":"Ann. Emerg. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.mayocp.2020.08.001","article-title":"Dysphagia in Older Adults","volume":"96","author":"Thiyagalingam","year":"2021","journal-title":"Mayo Clin. Proc."},{"key":"ref_68","unstructured":"Bayer PLC (2025, April 25). Xarelto 15 mg & 20 mg Film-Coated Tablets Treatment Initiation Pack. Available online: https:\/\/www.medicines.org.uk\/emc\/product\/8419\/smpc#gref."},{"key":"ref_69","unstructured":"Boehringer Ingelheim Ltd. (2025, April 25). Pradaxa 150 mg Hard Capsules. Available online: https:\/\/www.medicines.org.uk\/emc\/product\/4703\/smpc."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1016\/j.clinthera.2016.05.004","article-title":"Evaluation of crushed tablet for oral administration and the effect of food on apixaban pharmacokinetics in healthy adults","volume":"38","author":"Song","year":"2016","journal-title":"Clin. Ther."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/j.clinthera.2015.05.497","article-title":"Relative Bioavailability of Apixaban Solution or Crushed Tablet Formulations Administered by Mouth or Nasogastric Tube in Healthy Subjects","volume":"37","author":"Song","year":"2015","journal-title":"Clin. Ther."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1002\/cpdd.1156","article-title":"Bioequivalence and Pharmacokinetic Study of 2 Edoxaban Tablets in Healthy Chinese Subjects","volume":"11","author":"Liu","year":"2022","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1177\/0091270010370974","article-title":"Effects of food on the pharmacokinetics of edoxaban, an oral direct factor Xa inhibitor, in healthy volunteers","volume":"51","author":"Mendell","year":"2011","journal-title":"J. Clin. Pharmacol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s40262-017-0554-0","article-title":"An Open-Label Crossover Study of the Pharmacokinetics of the 60-mg Edoxaban Tablet Crushed and Administered Either by a Nasogastric Tube or in Apple Puree in Healthy Adults","volume":"57","author":"Duchin","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Cappannoli, L., Laborante, R., Galli, M., Canonico, F., Ciliberti, G., Restivo, A., Princi, G., Arcudi, A., Sabatelli, M., and De Cristofaro, R. (2022). Feasibility, effectiveness, and safety of edoxaban administration through percutaneous endoscopic gastrostomy: 12-months follow up of the ORIGAMI study. Front. Cardiovasc. Med., 9.","DOI":"10.3389\/fcvm.2022.1052053"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40262-013-0100-7","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban","volume":"53","author":"Mueck","year":"2014","journal-title":"Clin. Pharmacokinet."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"549","DOI":"10.5414\/CP201812","article-title":"The effect of food on the absorption and pharmacokinetics of rivaroxaban","volume":"51","author":"Stampfuss","year":"2013","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/cpdd.123","article-title":"Rivaroxaban crushed tablet suspension characteristics and relative bioavailability in healthy adults when administered orally or via nasogastric tube","volume":"3","author":"Moore","year":"2014","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1177\/0091270005274550","article-title":"Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement","volume":"45","author":"Stangier","year":"2005","journal-title":"J. Clin. Pharmacol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"55","DOI":"10.15420\/aer.2017.50.1","article-title":"The Significance of Drug-Drug and Drug-Food Interactions of Oral Anticoagulation","volume":"7","author":"Vranckx","year":"2018","journal-title":"Arrhythmia Electrophysiol. Rev."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.jacc.2019.12.068","article-title":"Select Drug-Drug Interactions with Direct Oral Anticoagulants: JACC Review Topic of the Week","volume":"75","author":"Wiggins","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Ferri, N., Colombo, E., Tenconi, M., Baldessin, L., and Corsini, A. (2022). Drug-Drug Interactions of Direct Oral Anticoagulants (DOACs): From Pharmacological to Clinical Practice. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14061120"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/JCP.0000000000001958","article-title":"Does Concomitant Use of Antidepressants and Direct Oral Anticoagulants Increase the Risk of Bleeding?: A Systematic Review and Meta-Analysis","volume":"45","author":"Weng","year":"2025","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/cpt.1146","article-title":"Serious Hypoglycemia and Use of Warfarin in Combination with Sulfonylureas or Metformin","volume":"105","author":"Nam","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.nut.2016.01.011","article-title":"Beneficial role of vitamin K supplementation on insulin sensitivity, glucose metabolism, and the reduced risk of type 2 diabetes: A review","volume":"32","author":"Manna","year":"2016","journal-title":"Nutrition"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/ehjcvp\/pvad038","article-title":"Risk of serious hypoglycaemia in patients with atrial fibrillation and diabetes concurrently taking antidiabetic drugs and oral anticoagulants: A nationwide cohort study","volume":"9","author":"Huang","year":"2023","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"9923772","DOI":"10.1155\/cdr\/9923772","article-title":"Effectiveness and Safety of Dose-Specific DOACs in Patients with Atrial Fibrillation: A Systematic Review and Network Meta-Analysis","volume":"2025","author":"Oh","year":"2025","journal-title":"Cardiovasc. Ther."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/jth.12485","article-title":"Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: A systematic review and meta-analysis","volume":"12","author":"Kooiman","year":"2014","journal-title":"J. Thromb. Haemost."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.archger.2018.12.013","article-title":"Non-vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation: A systematic review with meta-analysis and trial sequential analysis","volume":"81","author":"Caldeira","year":"2019","journal-title":"Arch. Gerontol. Geriatr."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e03","DOI":"10.15420\/ecr.2024.17","article-title":"Direct Oral Anticoagulant Use in Older Adults with Atrial Fibrillation: Challenges and Solutions","volume":"20","author":"Bhandari","year":"2025","journal-title":"Eur. Cardiol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/joim.13140","article-title":"Oral anticoagulants for nonvalvular atrial fibrillation in frail elderly patients: Insights from the ARISTOPHANES study","volume":"289","author":"Lip","year":"2021","journal-title":"J. Intern. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.121.056355","article-title":"Direct Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials with Interaction Testing by Age and Sex","volume":"145","author":"Carnicelli","year":"2022","journal-title":"Circulation"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"911","DOI":"10.2147\/CLEP.S219335","article-title":"Differences in Gastrointestinal Safety Profiles Among Novel Oral Anticoagulants: Evidence From A Network Meta-Analysis","volume":"11","author":"Guo","year":"2019","journal-title":"Clin. Epidemiol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/blood-2014-04-571232","article-title":"Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: Evidence from phase 3 trials","volume":"124","author":"Coppens","year":"2014","journal-title":"Blood"},{"key":"ref_95","first-page":"w14356","article-title":"Direct oral anticoagulants in the elderly: Systematic review and meta-analysis of evidence, current and future directions","volume":"146","author":"Sadlon","year":"2016","journal-title":"Swiss Med. Wkly."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1177\/15385744241253201","article-title":"Efficacy and Safety of Direct Oral Anticoagulants for Acute Treatment of Venous Thromboembolism in Older Adults: A Network Meta-Analysis of Randomised Controlled Trials","volume":"58","author":"Pessoa","year":"2024","journal-title":"Vasc. Endovasc. Surg."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1159\/000528606","article-title":"Comparative Safety and Effectiveness of Direct Oral Anticoagulants and Warfarin during Chemotherapy in Cancer Patients with Venous Thromboembolism Aged 75 Years or Older: A Nationwide Inpatient Database Study","volume":"69","author":"Iwai","year":"2023","journal-title":"Gerontology"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","article-title":"Dabigatran versus warfarin in patients with mechanical heart valves","volume":"369","author":"Eikelboom","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"EVIDoa2300067","DOI":"10.1056\/EVIDoa2300067","article-title":"Apixaban or Warfarin in Patients with an On-X Mechanical Aortic Valve","volume":"2","author":"Wang","year":"2023","journal-title":"NEJM Evid."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jacc.2022.10.008","article-title":"Direct Oral Anticoagulants vs Vitamin K Antagonists in Patients with Antiphospholipid Syndromes: Meta-Analysis of Randomized Trials","volume":"81","author":"Khairani","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"101116","DOI":"10.1016\/j.jhepr.2024.101116","article-title":"Direct oral anticoagulants in cirrhosis: Rationale and current evidence","volume":"6","author":"Portela","year":"2024","journal-title":"JHEP Rep."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Krittayaphong, R., Chantrarat, T., Rojjarekampai, R., Jittham, P., Sairat, P., and Lip, G.Y.H. (2020). Poor Time in Therapeutic Range Control is Associated with Adverse Clinical Outcomes in Patients with Non-Valvular Atrial Fibrillation: A Report from the Nationwide COOL-AF Registry. J. Clin. Med., 9.","DOI":"10.3390\/jcm9061698"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Kosum, P., Siranart, N., Nissaipan, K., Laohapiboolrattana, W., Sowalertrat, W., Triamamornwooth, K., Arunphan, R., Sriyom, A., and Rungpradubvong, V. (2024). Utility of TTR-INR guided warfarin adjustment protocol to improve time in therapeutic range in patients with atrial fibrillation receiving warfarin. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-61664-5"},{"key":"ref_104","first-page":"534","article-title":"Evaluation of Warfarin Patients with Low Time in Therapeutic Range (TTR) for Transition to Non-Vitamin-K Oral Anticoagulant (NOAC) Therapy","volume":"44","author":"Fovel","year":"2019","journal-title":"Pharm. Ther."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"e020904","DOI":"10.1161\/JAHA.121.020904","article-title":"Direct Oral Anticoagulant Adherence of Patients with Atrial Fibrillation Transitioned from Warfarin","volume":"10","author":"Pundi","year":"2021","journal-title":"J. Am. Heart Assoc."},{"key":"ref_106","first-page":"279","article-title":"Safety of Switching From a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients with Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial","volume":"149","author":"Joosten","year":"2024","journal-title":"Circulation"},{"key":"ref_107","first-page":"366","article-title":"Out-of-pocket costs for direct oral anticoagulants and prescription abandonment among patients with nonvalvular atrial fibrillation or venous thromboembolism","volume":"31","author":"Zhdanava","year":"2025","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1136\/bmjebm-2020-111634","article-title":"Economic evaluation of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) for stroke prevention in patients with atrial fibrillation: A systematic review and meta-analysis","volume":"27","author":"Noviyani","year":"2022","journal-title":"BMJ Evid. Based Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"A1","DOI":"10.1093\/eurheartj\/suab150","article-title":"Non-vitamin K antagonist oral anticoagulants in older and frail patients with atrial fibrillation","volume":"24","author":"Giugliano","year":"2022","journal-title":"Eur. Heart J. Suppl."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1016\/j.jacc.2017.09.1091","article-title":"NOAC Dosing in Atrial Fibrillation and Renal Dysfunction: What Measure Are You Using?","volume":"70","author":"Shroff","year":"2017","journal-title":"JACC"},{"key":"ref_111","first-page":"e30230","article-title":"Safety and Efficacy of Apixaban vs Warfarin in Patients with Stage 4 and 5 Chronic Kidney Disease: A Systematic Review","volume":"14","author":"Fatima","year":"2022","journal-title":"Cureus"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1016\/j.jacc.2017.09.1087","article-title":"Renal Outcomes in Anticoagulated Patients with Atrial Fibrillation","volume":"70","author":"Yao","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1111\/jgs.16992","article-title":"Muscle Mass and Direct Oral Anticoagulant Activity in Older Adults with Atrial Fibrillation","volume":"69","author":"Bendayan","year":"2021","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1056\/NEJMoa2012883","article-title":"Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation","volume":"383","author":"Okumura","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1093\/ehjcvp\/pvad058","article-title":"Clinical outcomes in elderly atrial fibrillation patients at increased bleeding risk treated with very low dose vs. regular-dose non-vitamin K antagonist oral anticoagulants: A nationwide cohort study","volume":"9","author":"Chan","year":"2023","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/13\/4396\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:55:38Z","timestamp":1760032538000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/13\/4396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,20]]},"references-count":115,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["jcm14134396"],"URL":"https:\/\/doi.org\/10.3390\/jcm14134396","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,20]]}}}